Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZYLOPRIM vs FEBUXOSTAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.
Gout: management of chronic, primary, or secondary gout,Hyperuricemia associated with chemotherapy: prevention of acute uric acid nephropathy in patients with leukemia, lymphoma, and solid tumor malignancies receiving chemotherapy,Recurrent calcium oxalate calculi: prevention in patients with hyperuricosuria
Chronic management of hyperuricemia in patients with gout,Off-label: Prevention of tumor lysis syndrome,Off-label: Management of hyperuricemia in kidney transplant recipients
100-300 mg orally once daily, maximum 800 mg/day.
40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.
Allopurinol: 1-2 hours; oxypurinol: 18-30 hours (prolonged to 48-72 hours in renal impairment). Clinical context: oxypurinol half-life determines dosing interval; dose adjustment required for Cr Cl < 20 m L/min.
Terminal elimination half-life: 5-8 hours in healthy subjects; prolonged in renal impairment (e.g., up to 9.6 hours in moderate impairment). Clinical context: dosing interval is once daily, consistent with half-life.
Allopurinol is metabolized primarily by aldehyde oxidase to its active metabolite, oxypurinol; both are excreted renally.
Primarily metabolized by conjugation via UDP-glucuronosyltransferases (UGT1A1, UGT1A3, UGT1A9, and UGT2B7) and oxidation via cytochrome P450 (CYP) enzymes, including CYP1A2, CYP2C8, and CYP2C9, with minor contribution from CYP3A4/5.
Renal: allopurinol ~10% unchanged, oxypurinol ~70% unchanged; total renal elimination ~76% (allopurinol + oxypurinol); fecal/biliary: minor (~12-20% as allopurinol, ~3-5% as oxypurinol).
Renal: 1-3% unchanged; biliary/fecal: ~50% as metabolites (acyl glucuronides, oxidative metabolites); other: ~49% metabolized and eliminated via multiple pathways including biliary and direct intestinal excretion of unchanged drug.
Allopurinol: <1% bound; oxypurinol: ~17-20% bound (primarily to albumin).
99% (primarily to albumin; minor binding to alpha-1-acid glycoprotein).
Allopurinol: ~1.6 L/kg; oxypurinol: ~0.4-0.6 L/kg. Clinical meaning: allopurinol distributes widely into total body water, while oxypurinol has a smaller Vd consistent with limited tissue distribution.
Approximately 0.7 L/kg (indicating distribution into total body water; not extensively tissue-bound).
Oral: allopurinol 67-90% (mean ~80%); oxypurinol formed via first-pass metabolism has an effective systemic exposure.
Oral: at least 49% (absolute bioavailability not established; estimated based on mass balance studies).
Cr Cl >60 m L/min: no adjustment; Cr Cl 30-60 m L/min: 200 mg daily; Cr Cl 10-30 m L/min: 100 mg daily; Cr Cl <10 m L/min: 100 mg every 2-3 days or 50 mg daily.
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). For severe renal impairment (e GFR <30 m L/min), limited data; use with caution, not recommended in dialysis.
No specific guidelines; use with caution in severe hepatic impairment.
Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: not recommended (no studies).
6-10 years: 150 mg/day; 11-16 years: 300 mg/day; <6 years: 50 mg/day; all given orally once daily.
Not approved for pediatric use; safety and efficacy not established.
Start at lower dose (100 mg daily) due to reduced renal function; titrate to achieve serum urate target.
No specific dose adjustment required; use with caution due to potential for decreased renal function.
None
Increased risk of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent revascularization in patients with established cardiovascular disease (based on the CARES trial). Febuxostat should be avoided in patients with a history of myocardial infarction or stroke, unless no other therapy is appropriate.
Allopurinol hypersensitivity syndrome (AHS) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); increased risk in patients with HLA-B*5801 allele; renal impairment requires dose adjustment; use with caution in patients with liver dysfunction; may cause drowsiness or dizziness; discontinue at first sign of rash or other signs of hypersensitivity.
Cardiovascular events (see black box warning); hepatotoxicity (elevated liver enzymes, hepatic failure); gout flares upon initiation (prophylaxis recommended); renal impairment (dose adjustment for severe impairment); hypersensitivity reactions (including Stevens-Johnson syndrome); thyroid function abnormalities (elevated TSH).
Absolute: known hypersensitivity to allopurinol or any component of the formulation. Relative: concomitant use with didanosine; severe renal impairment (Cr Cl <10 m L/min) unless used for prevention of uric acid nephropathy during chemotherapy.
Concurrent use with azathioprine, 6-mercaptopurine, or theophylline (due to risk of toxicity); severe renal impairment (Cr Cl <30 m L/min) based on trial data; history of myocardial infarction or stroke (relative contraindication per FDA).
High-purine foods (e.g., organ meats, anchovies, sardines, mussels, beer) should be avoided as they increase uric acid levels. No significant food-drug interactions besides alcohol.
No specific food interactions are reported, but high-purine foods (red meat, organ meats, shellfish) and alcohol may increase serum urate and counteract drug efficacy; advise moderation and limit intake during therapy.
Allopurinol (Zyloprim) is a xanthine oxidase inhibitor. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: No known increased risk; use only if clearly needed. Overall FDA pregnancy category C.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, febuxostat caused developmental toxicity (reduced fetal weight, increased skeletal variations) at maternal toxic doses. First trimester: unknown risk; avoid unless benefits outweigh risks. Second/third trimester: limited data; potential for fetal harm based on animal findings.
Allopurinol and its metabolite oxypurinol are excreted into human breast milk. Milk-to-plasma ratio approximately 0.9-1.4 for allopurinol and 0.5-0.9 for oxypurinol. No adverse effects reported in infants. Considered compatible with breastfeeding given very low infant dose (<2% of maternal weight-adjusted dose).
Excretion in human milk unknown; M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy.
No specific dose adjustment required during pregnancy. However, pregnancy can increase renal clearance; monitor serum uric acid levels and adjust dose if necessary. Maintain lowest effective dose.
No specific pharmacokinetic data in pregnancy. Due to potential teratogenicity, avoid in pregnancy. If use is unavoidable, no dose adjustment studies exist; use lowest effective dose with caution.
Monitor serum uric acid levels monthly until goal is achieved; titrate every 2-4 weeks. Avoid use in acute gout flares; start after inflammation subsides. Check renal function and adjust dose accordingly (Cr Cl <30 m L/min: max 200 mg/day). Consider HLA-B*5801 screening in Han Chinese, Thai, or Korean patients to prevent severe hypersensitivity. Allopurinol hypersensitivity syndrome is rare but life-threatening; discontinue at first sign of rash. Concomitant azathioprine or 6-mercaptopurine requires dose reduction to 25-33% of original.
Febuxostat is a non-purine selective xanthine oxidase inhibitor indicated for chronic management of hyperuricemia in gout. It is contraindicated with concomitant azathioprine, mercaptopurine, or theophylline due to risk of toxicity. Initiate at 40 mg daily; titrate to 80 mg if serum urate not at target after 2 weeks. Monitor for gout flares during initiation; provide prophylactic NSAIDs or colchicine for at least 6 months. Cardiovascular risk: increased risk of cardiovascular death vs allopurinol in patients with history of CV disease; avoid as first-line or in patients with prior MI or stroke. Assess liver function tests at baseline and periodically; discontinue if persistent elevation >3x ULN or signs of liver injury. Not recommended in patients with severe hepatic impairment (Child-Pugh C).
Take exactly as prescribed; do not miss doses.,Drink at least 8 glasses of water daily to prevent kidney stones.,Report rash, itching, or swelling immediately; may indicate severe allergic reaction.,Avoid alcohol, especially beer and liquor, which can increase uric acid.,Use with caution if you have kidney disease; your dose may need adjustment.,Do not start or stop other medications like diuretics without consulting your doctor.,This drug prevents gout attacks, so continue even if you feel well.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.,You may experience gout flares during the first few months; continue your medication and take prescribed anti-inflammatory drugs as directed.,Report any signs of heart attack or stroke (chest pain, shortness of breath, weakness on one side of body, slurred speech) immediately.,Avoid alcohol, especially beer, which can increase uric acid levels and trigger gout flares.,Inform your doctor if you are taking azathioprine, mercaptopurine, or theophylline; these are not safe to take with febuxostat.,If you have a history of heart attack, stroke, or heart disease, discuss alternative treatments with your doctor.,Seek medical attention for signs of liver injury (yellow skin/eyes, dark urine, abdominal pain, persistent nausea).,Stay hydrated to help prevent kidney stones; aim for 8-10 glasses of water daily unless otherwise advised.,Do not crush or chew tablets; swallow whole with water.
No interactions on record
"Mercaptopurine is metabolized by xanthine oxidase. Febuxostat inhibits xanthine oxidase, leading to significantly reduced clearance of mercaptopurine and its active metabolites. This can result in severe myelosuppression, including life-threatening neutropenia and thrombocytopenia, as well as hepatotoxicity."
"The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat."
"The serum concentration of Febuxostat can be increased when it is combined with Azathioprine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZYLOPRIM vs FEBUXOSTAT, answered by our medical review team.
ZYLOPRIM is a Xanthine Oxidase Inhibitor that works by Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. FEBUXOSTAT is a Xanthine Oxidase Inhibitor that works by Febuxostat is a non-purine selective inhibitor of xanthine oxidase (XO). It inhibits both oxidized and reduced forms of XO, thereby reducing the conversion of hypoxanthine to xanthine and xanthine to uric acid, leading to decreased serum uric acid levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZYLOPRIM and FEBUXOSTAT depend on the specific clinical indication. These are both Xanthine Oxidase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZYLOPRIM is: 100-300 mg orally once daily, maximum 800 mg/day.. The standard adult dose of FEBUXOSTAT is: 40 mg orally once daily; may increase to 80 mg orally once daily if serum urate goal not achieved after 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZYLOPRIM and FEBUXOSTAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZYLOPRIM is classified as Category C. Allopurinol (Zyloprim) is a xanthine oxidase inhibitor. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second . FEBUXOSTAT is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, febuxostat caused developmental toxicity (reduced fetal weight, increased skeletal variations) at ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.